Differential Expression of Thromboxane Synthase in Prostate Carcinoma

Role in Tumor Cell Motility

Daotai Nie, Mingxin Che, Alex Zacharek, Yan Qiao, Li Li, Xinglin Li, Mario Lamberti, Keqin Tang, Yilong Cai, Yande Guo, David Grignon, Kenneth V. Honn

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Arachidonic acid metabolism through cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoids. Thromboxane synthase (TxS) metabolizes the cyclooxygenase product, prostanglandin H 2, into thromboxane A2 (TXA2), which can cause vessel constriction, platelet activation, and aggregation. Here we demonstrate that human prostate cancer (PCa) cells express enzymatically active TxS and that this enzyme is involved in cell motility. In human PCa cell lines, PC-3, PC-3M, and ML-2 cells expressed higher levels of TxS than normal prostate epithelial cells or other established PCa cell lines such as DU145, LNCaP, or PPC-1. We cloned and sequenced the full-length TxS cDNA from PC-3 cells and found two changes in the amino acid residues. Immunohistochemical analysis of tumor specimens revealed that expression of TxS is weak or absent in normal differentiated luminal, or secretory cells, significantly elevated in less differentiated or advanced prostate tumors, and markedly increased in tumors with perineural invasion. TxS expressed in PC-3 cells was enzymatically active and susceptible to carboxyheptal imidazole, an inhibitor of TxS. The biosynthesis of TXA2 in PC-3 cells was dependent on COX-2, and to a lesser extent, COX-1. Treatment of PC-3 cells with a COX-1 selective inhibitor, piroxicam, reduced TXA2 synthesis by approximately 40%, while the COX-2 specific inhibitor NS398 reduced TXA2 production by ∼80%. Inhibition of TxS activity or blockade of TXA2 function reduced PC-3 cell migration on fibronectin, while having minimal effects on cell cycle progression or survival. Finally, increased expression of TxS in DU145 cells increased cell motility. Our data suggest that human PCa cells express TxS and that this enzyme may contribute to PCa progression through modulating cell motility.

Original languageEnglish (US)
Pages (from-to)429-439
Number of pages11
JournalAmerican Journal of Pathology
Volume164
Issue number2
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Thromboxanes
Cell Movement
Prostate
Carcinoma
Thromboxane A2
Neoplasms
Prostatic Neoplasms
Prostaglandin-Endoperoxide Synthases
Piroxicam
Cell Line
Lipoxygenase
Eicosanoids
Cyclooxygenase 2 Inhibitors
Platelet Activation
Enzymes
Platelet Aggregation
Fibronectins
Arachidonic Acid
Constriction
Cell Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Nie, D., Che, M., Zacharek, A., Qiao, Y., Li, L., Li, X., ... Honn, K. V. (2004). Differential Expression of Thromboxane Synthase in Prostate Carcinoma: Role in Tumor Cell Motility. American Journal of Pathology, 164(2), 429-439.

Differential Expression of Thromboxane Synthase in Prostate Carcinoma : Role in Tumor Cell Motility. / Nie, Daotai; Che, Mingxin; Zacharek, Alex; Qiao, Yan; Li, Li; Li, Xinglin; Lamberti, Mario; Tang, Keqin; Cai, Yilong; Guo, Yande; Grignon, David; Honn, Kenneth V.

In: American Journal of Pathology, Vol. 164, No. 2, 02.2004, p. 429-439.

Research output: Contribution to journalArticle

Nie, D, Che, M, Zacharek, A, Qiao, Y, Li, L, Li, X, Lamberti, M, Tang, K, Cai, Y, Guo, Y, Grignon, D & Honn, KV 2004, 'Differential Expression of Thromboxane Synthase in Prostate Carcinoma: Role in Tumor Cell Motility', American Journal of Pathology, vol. 164, no. 2, pp. 429-439.
Nie, Daotai ; Che, Mingxin ; Zacharek, Alex ; Qiao, Yan ; Li, Li ; Li, Xinglin ; Lamberti, Mario ; Tang, Keqin ; Cai, Yilong ; Guo, Yande ; Grignon, David ; Honn, Kenneth V. / Differential Expression of Thromboxane Synthase in Prostate Carcinoma : Role in Tumor Cell Motility. In: American Journal of Pathology. 2004 ; Vol. 164, No. 2. pp. 429-439.
@article{9e6f11a19bda41d89c15c38820795870,
title = "Differential Expression of Thromboxane Synthase in Prostate Carcinoma: Role in Tumor Cell Motility",
abstract = "Arachidonic acid metabolism through cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoids. Thromboxane synthase (TxS) metabolizes the cyclooxygenase product, prostanglandin H 2, into thromboxane A2 (TXA2), which can cause vessel constriction, platelet activation, and aggregation. Here we demonstrate that human prostate cancer (PCa) cells express enzymatically active TxS and that this enzyme is involved in cell motility. In human PCa cell lines, PC-3, PC-3M, and ML-2 cells expressed higher levels of TxS than normal prostate epithelial cells or other established PCa cell lines such as DU145, LNCaP, or PPC-1. We cloned and sequenced the full-length TxS cDNA from PC-3 cells and found two changes in the amino acid residues. Immunohistochemical analysis of tumor specimens revealed that expression of TxS is weak or absent in normal differentiated luminal, or secretory cells, significantly elevated in less differentiated or advanced prostate tumors, and markedly increased in tumors with perineural invasion. TxS expressed in PC-3 cells was enzymatically active and susceptible to carboxyheptal imidazole, an inhibitor of TxS. The biosynthesis of TXA2 in PC-3 cells was dependent on COX-2, and to a lesser extent, COX-1. Treatment of PC-3 cells with a COX-1 selective inhibitor, piroxicam, reduced TXA2 synthesis by approximately 40{\%}, while the COX-2 specific inhibitor NS398 reduced TXA2 production by ∼80{\%}. Inhibition of TxS activity or blockade of TXA2 function reduced PC-3 cell migration on fibronectin, while having minimal effects on cell cycle progression or survival. Finally, increased expression of TxS in DU145 cells increased cell motility. Our data suggest that human PCa cells express TxS and that this enzyme may contribute to PCa progression through modulating cell motility.",
author = "Daotai Nie and Mingxin Che and Alex Zacharek and Yan Qiao and Li Li and Xinglin Li and Mario Lamberti and Keqin Tang and Yilong Cai and Yande Guo and David Grignon and Honn, {Kenneth V.}",
year = "2004",
month = "2",
language = "English (US)",
volume = "164",
pages = "429--439",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Differential Expression of Thromboxane Synthase in Prostate Carcinoma

T2 - Role in Tumor Cell Motility

AU - Nie, Daotai

AU - Che, Mingxin

AU - Zacharek, Alex

AU - Qiao, Yan

AU - Li, Li

AU - Li, Xinglin

AU - Lamberti, Mario

AU - Tang, Keqin

AU - Cai, Yilong

AU - Guo, Yande

AU - Grignon, David

AU - Honn, Kenneth V.

PY - 2004/2

Y1 - 2004/2

N2 - Arachidonic acid metabolism through cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoids. Thromboxane synthase (TxS) metabolizes the cyclooxygenase product, prostanglandin H 2, into thromboxane A2 (TXA2), which can cause vessel constriction, platelet activation, and aggregation. Here we demonstrate that human prostate cancer (PCa) cells express enzymatically active TxS and that this enzyme is involved in cell motility. In human PCa cell lines, PC-3, PC-3M, and ML-2 cells expressed higher levels of TxS than normal prostate epithelial cells or other established PCa cell lines such as DU145, LNCaP, or PPC-1. We cloned and sequenced the full-length TxS cDNA from PC-3 cells and found two changes in the amino acid residues. Immunohistochemical analysis of tumor specimens revealed that expression of TxS is weak or absent in normal differentiated luminal, or secretory cells, significantly elevated in less differentiated or advanced prostate tumors, and markedly increased in tumors with perineural invasion. TxS expressed in PC-3 cells was enzymatically active and susceptible to carboxyheptal imidazole, an inhibitor of TxS. The biosynthesis of TXA2 in PC-3 cells was dependent on COX-2, and to a lesser extent, COX-1. Treatment of PC-3 cells with a COX-1 selective inhibitor, piroxicam, reduced TXA2 synthesis by approximately 40%, while the COX-2 specific inhibitor NS398 reduced TXA2 production by ∼80%. Inhibition of TxS activity or blockade of TXA2 function reduced PC-3 cell migration on fibronectin, while having minimal effects on cell cycle progression or survival. Finally, increased expression of TxS in DU145 cells increased cell motility. Our data suggest that human PCa cells express TxS and that this enzyme may contribute to PCa progression through modulating cell motility.

AB - Arachidonic acid metabolism through cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoids. Thromboxane synthase (TxS) metabolizes the cyclooxygenase product, prostanglandin H 2, into thromboxane A2 (TXA2), which can cause vessel constriction, platelet activation, and aggregation. Here we demonstrate that human prostate cancer (PCa) cells express enzymatically active TxS and that this enzyme is involved in cell motility. In human PCa cell lines, PC-3, PC-3M, and ML-2 cells expressed higher levels of TxS than normal prostate epithelial cells or other established PCa cell lines such as DU145, LNCaP, or PPC-1. We cloned and sequenced the full-length TxS cDNA from PC-3 cells and found two changes in the amino acid residues. Immunohistochemical analysis of tumor specimens revealed that expression of TxS is weak or absent in normal differentiated luminal, or secretory cells, significantly elevated in less differentiated or advanced prostate tumors, and markedly increased in tumors with perineural invasion. TxS expressed in PC-3 cells was enzymatically active and susceptible to carboxyheptal imidazole, an inhibitor of TxS. The biosynthesis of TXA2 in PC-3 cells was dependent on COX-2, and to a lesser extent, COX-1. Treatment of PC-3 cells with a COX-1 selective inhibitor, piroxicam, reduced TXA2 synthesis by approximately 40%, while the COX-2 specific inhibitor NS398 reduced TXA2 production by ∼80%. Inhibition of TxS activity or blockade of TXA2 function reduced PC-3 cell migration on fibronectin, while having minimal effects on cell cycle progression or survival. Finally, increased expression of TxS in DU145 cells increased cell motility. Our data suggest that human PCa cells express TxS and that this enzyme may contribute to PCa progression through modulating cell motility.

UR - http://www.scopus.com/inward/record.url?scp=1542379730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542379730&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 429

EP - 439

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -